Acta Scientific Women's Health (ASWH)(ISSN: 2582-3205)

Case Report Volume 4 Issue 5

A Case of Telogen Effluvium as COVID Sequelae

Gurdeep Singh1*, Sarthak Parikh2 and Ujval Choksi3

1Internal Medicine/Endocrinology, Our Lady of Lourdes Memorial Hospital, Binghamton, NY, USA
2Nova Southeastern University College of Osteopathic Medicine, Monroe, NJ, USA
3Our Lady of Lourdes Memorial Hospital, Binghamton, NY, USA

*Corresponding Author: Gurdeep Singh, Internal Medicine/Endocrinology, Our Lady of Lourdes Memorial Hospital, Binghamton, NY, USA.

Received: March 15, 2022; Published: April 29, 2022

Abstract

Telogen effluvium (TE) is a reversible form of hair loss which is an identified sequela of COVID-19 infection. Generally diagnosed by a hair-pull test or a modified wash test, it can cause a non-scarring shedding of hair for months after the resolution of COVID-19. The pathophysiology of TE secondary to COVID-19 is still being understood. Here, we describe a 45-year-old unvaccinated female who was diagnosed with a severe case of telogen effluvium approximately 3 months after her COVID-19 diagnosis, with hair loss that exceeded 80% of her total hair.

Keywords: Telogen Effluvium; COVID 19; Hair Loss

References

  1. Shi Y., et al. “An overview of COVID-19”. Journal of Zhejiang University Science B5 (2020): 343-360.
  2. Abrantes TF., et al. “Time of onset and duration of post-COVID-19 acute telogen effluvium”. Journal of the American Academy of Dermatology4 (2021): 975-976.
  3. Gruenstein D., et al. “Telogen effluvium caused by COVID-19 in Elmhurst, New York: report of a cohort and review”. DOJ10 (2021).
  4. Mieczkowska K., et al. “Telogen effluvium: a sequelae of COVID‐19”. International Journal of Dermatology1 (2021): 122-124.
  5. Olds H., et al. “Telogen effluvium associated with COVID‐19 infection”. Dermatologic Therapy2 (2020).
  6. Chien Yin GO., et al. “Telogen Effluvium – a review of the science and current obstacles”. Journal of Dermatological Science3 (2021): 156-163.
  7. Seleit I., et al. “Vitamin D Receptor Gene Polymorphism In Chronic Telogen Effluvium; A Case-Control Study”. CCID 12 (2019)745-750.
  8. Manolis AS., et al. “COVID-19 Infection: Viral Macro- and Micro-Vascular Coagulopathy and Thromboembolism/Prophylactic and Therapeutic Management”. Journal of Cardiovascular Pharmacology and Therapeutics 1 (2021): 12-24.
  9. Hussain N., et al. “A systematic review of acute telogen effluvium, a harrowing post-COVID-19 manifestation”. Journal of Medical Virology4 (2022): 1391-1401.
  10. Aksoy H., et al. “COVID-19 induced telogen effluvium”. Dermatology Therapy 34.6 (2021): e15175.
  11. Trüeb RM. “Telogen Effluvium: Is There a Need for a New Classification?”. Skin Appendage Disorder1-2 (2016): 39-44.
  12. Rebora A. “Telogen effluvium: a comprehensive review”. Clinical, Cosmetic and Investigational Dermatology 12 (2019): 583-590.
  13. Sharquie KE and Jabbar RI. “COVID-19 infection is a major cause of acute telogen effluvium”. Irish Journal of Medical Science (2021): 1-5.
  14. Otsuka Y., et al. “Recovery From Alopecia After COVID-19”. Cureus 1 (2022): e21160.

Citation

Citation: Gurdeep Singh., et al. “A Case of Telogen Effluvium as COVID Sequelae". Acta Scientific Women's Health 4.5 (2022): 66-69.

Copyright

Copyright: © 2022 Gurdeep Singh., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days

Indexed In





News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 10, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US